2 results
Approved WMORecruiting
To assess the safety and efficacy of the FANTOM ENCORE sirolimus-eluting BRS.
Approved WMORecruiting
Phase 2:Primary ObjectivesTo determine the recommended Phase3 dose of mitapivat by evaluating the effect of 2 dose levels of mitapivat versus placebo on:• Anemia in subjects with sickle cell disease (SCD)• SafetySecondary ObjectivesTo evaluate the…